- Pledge to Africa Act
The
Jean Chrétien Pledge toAfrica Act (in full: "An Act to amend the Patent Act and the Food and Drugs Act"), was a bill introduced as C-9 in the third session of the37th Canadian Parliament . It was the first implementation of theTRIPS flexibilities declared in theAugust 30 ,2003 , General Council decision. Enacted in May 2004, it allows Canada to enact compulsory licenses to exportessential medicines to countries without the capacity to manufacture their own. Other countries that have since enacted similar legislation areNorway andIndia .Purpose
The purpose of the Act is to improve access to drugs for developing countries that can't manufacture the drugs or can't manufacture the drugs or afford to buy them. http://www.stephenlewisfoundation.org/documents/SLFNewsletter2005.pdf] It is specifically targeted at allowing generic production of drugs that can help fight HIV/AIDS. The drugs that fight these diseases are expensive to create and manufacture and thus are usually unaffordable for those who need them the most. [http://works.bepress.com/matthew_rimmer/12/ The Jean Chrétien Pledge to Africa Act: Patent Law and Humanitarian Aid ] ]
The Pledge to Africa Act allows for the patents on these drugs to be overridden when manufactures are producing generic versions of the drug to sell in third world countries.
Criticisms
The act has come under some criticism. [http://www.yorku.ca/dapina/lw2970/ip/?p=188 ipilogue » Blog Archive » Is Canada Delivering on its Pledge to Aid Africa? ] ] [http://www.law.utoronto.ca/accesstodrugs/History.htm Access to Drugs Initiative - History ] ] http://www.icad-cisd.com/pdf/publications/ACCESS_FSandCaseStudies_FINALAug4_06_EN.pdf] It took a full year from the time the bill was introduced to the time that it came into effect. Since the act was came into effect in 2005 not a single drug has been manufactured and exported under the act.
The process for obtaining the exceptions to the patents for the drugs is expensive and has to be renewed every two years and makes the production of generic drugs not necessarily economically viable for companies.
As well exporting to countries that are not part of the WTO TRIPS agreement is made more difficult by further restrictions.
References and notes
ee also
External links
*http://www.aidslaw.ca/Maincontent/issues/cts/patent-amend.htm
*http://www.law.utoronto.ca/accesstodrugs/
Wikimedia Foundation. 2010.